Selexis says $2m investment will speed up cell bank delivery time

By Flora Southey contact

- Last updated on GMT

(Image: Getty/BrianAJackson)
(Image: Getty/BrianAJackson)
Cell line developer Selexis has invested in laboratory equipment to reduce delivery times of its high expressing and stable research cell banks.

The $2m (€1.6) investment will help the Switzerland-headquartered develop technologies and procedures aimed at reducing the 14-week process.

“We believe by combining whole-genome sequencing with novel clonal selection technologies, we can deliver an RBC [research cell bank] in eight to nine weeks,” ​CEO Igor Fisch told us.

“This can have a huge impact on helping partners get their promising candidates into the clinic faster,” ​he added.

A shift in demand

Fisch told us he has observed a shift in demand from monoclonal antibodies (mAbs) to more complex proteins, such as bi-specifics and FC-fusions.

This includes biotherapeutic proteins – that can be difficult-to-express in CHO (Chinese hamster ovary) cells – such as bi-specific proteins, DARPins, triabodies, and novel scaffolds decorated with peptides, enzymes, or growth factors, he said.

“We have spent a lot of time interrogating and characterizing our propriety CHO-K1 cell line (CHO-M),” ​he added.

In May last year​, Selexis opened its cell line development laboratory in Geneva, Switzerland. The following month, Selexis was acquired​ by contract development and manufacturing organization (CDMO) JSR Life Sciences.

In the same year, Selexis signed deals with Merck KGaA​, Pelican Therapeutics​, and Sanofi​, and this year entered an agreement with Compugen​ and resigned Xencor​ to boost their cell line development programmes.

Related topics: Upstream Processing, Cell lines

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us


View more